Inclusion Criteria:

- diagnosis of MM according to the SWOG criteria (annex 1)

- previously untreated (localized radiotherapy is allowed)

- symptomatic MM stage II or III according to Durie-Salmon staging system (annex 2) or
stage I with one symptomatic osteolytic lesion

- with measurable levels of paraprotein in the serum (> 1g/dl) or in the urine (>
0.2g/24h)

- age < 75 years

- able to understand and to given an informed consent

- male, female without childbearing potential or negative urine pregnancy test within
72 hours prior to beginning the treatment. Women of childbearing potential must be
following adequate contraceptive measures.

- no active systemic infection. In the presence of any active systemic infection,
adequate broad-spectrum or organism-specific antibiotic coverage must be
administered. Patients must be a febrile with stable vital signs while receiving
antibiotics for at least 48 hours prior to beginning the treatment with Velcade plus
dexamethasone.

Exclusion Criteria:

- life expectancy < 2 months

- ECOG performance status > 2 (annex 3)

- proven amyloidosis

- positive HIV serology

- antecedents of severe psychiatric disease

- severe diabetes contraindicating the use of high-dose corticoïds

- > NCI grade 2 peripheral neuropathy (Annex IV)

- serum biochemical values as follow

- creatinin level > 200mmol/l

- bilirubin, transaminases or gGT > 3 the upper normal limit

- use of any experimental drugs within 30 days of baseline